January 12, 2021
Oxford-based biotech company, Theolytics has announced the closing of a US $6.8 million (£5 million) Series A round.
The round was co-led by Epidarex Capital and Taiho Ventures LLC with participation from existing investor, Oxford Sciences Innovation (OSI).
The financing will be used to progress the company’s pipeline of candidates towards human clinical trials.
WHY IT MATTERS
November 12, 2018
Driver, the pricey mobile app designed to link cancer patients to appropriate treatment or relevant clinical trials, appears to have bitten off a bit more than it could chew. This morning STAT reported that the service, which only launched in September, ran out of funds and released its entire 85-employee staff in mid-October, effectively shuttering the business.
Driver CEO and cofounder Dr....